Search results
Results from the WOW.Com Content Network
Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination.
Monogenic obesity is excess weight caused by a mutation in a single gene, as opposed to syndromic obesity not tied to a single gene variation and most obesity, which is caused by multiple genetic and environmental risk factors. Monogenetic obesity mostly affects the hypothalamus and leptin–melanocortin system (see hypothalamic obesity ...
In the United States, the prevalence of obese or overweight adult dogs is 23–53%, of which about 5% are obese; [22] [23] the incidence in adult cats is 55%, [23] of which about 8% are obese. [22] In Australia, obesity is the most common nutritional disease of pets; [24] the prevalence of obesity in dogs in Australia is approximately 40%. [14]
When another multinational pharmaceutical giant develops a new drug for your dog, like an injection for diabetics that is now labeled as a weight control medication, or a new vaccine that may ...
As with humans, obesity can cause numerous health problems in dogs (although dogs are much less susceptible to the common cardiac and arterial consequences of obesity than humans are). According to a study published in the Journal of Veterinary Internal Medicine , the prevalence of obesity in dogs is between 22 and 40 percent.
pentoxyfylline – xanthine derivative used in as an antiinflammatory drug and in the prevention of endotoxemia; pergolide – dopamine receptor agonist used for the treatment of pituitary pars intermedia dysfunction in horses; phenobarbital – anti-convulsant used for seizures; phenylbutazone – nonsteroidal anti-inflammatory drug (NSAID)
Myostatin inhibitors are a class of drugs that work by blocking the effect of myostatin, which inhibits muscle growth. In animal models and limited human studies, myostatin inhibitors have increased muscle size. They are being developed to treat obesity, sarcopenia, muscular dystrophy, and other illnesses.
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body , weight regulation, by: reducing appetite and consequently energy intake , increasing energy expenditure , redirecting nutrients from adipose to lean ...